Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

The Chronic Kidney Disease Adaptive Platform Trial som undersøker ulike midler for terapeutisk effekt (CAPTIVATE)

29. september 2026 oppdatert av: The George Institute

CAPTIVATE is an international, multi-centre, Phase III, adaptive, platform, randomised controlled trial in people with chronic kidney disease (CKD).

CAPTIVATE aims to find the best treatment, or combination of treatments, that slow the progression of CKD so that fewer people develop kidney failure.

CAPTIVATE provides a research platform that allows many treatment-related questions to be answered within a common trial set-up.

CAPTIVATE includes multiple domains examining different therapies for CKD. Participants may enrol in one or more domains and domains will be added and closed over time. The platform operates under a core protocol with each domain described in a domain specific appendix.

Studieoversikt

Detaljert beskrivelse

Chronic kidney disease (CKD) affects over 800 million people globally and is projected to be the 5th most common cause of death by 2040. CKD progresses to kidney failure, increases the risk of early death, heart disease, and leads to a poorer quality of life.

Current treatments do not entirely remove the risk of kidney failure in people with CKD. To improve the outcomes of people with CKD, it is crucial to find the best treatment or combination of treatments that can slow CKD progression. CAPTIVATE aims to address this need.

CAPTIVATE has been designed to test multiple treatments within a common research platform. This design is more efficient and will lead to a shorter time for patients to receive effective treatments. The trial is 'eternal', which means that participants will continue to be recruited for many years until the trial is finally wound up. It is also 'adaptive', providing the flexibility to add new treatments, or remove those that are not working.

Participants can participate in more than one treatment at the same time or at different times. Participants receive each study treatment for 2 years. For each treatment, participants are followed up at study visits that occur at approximately one month, 3 months, 6 months, 12 months, 18 months and 2 years after starting treatment. A final study visit occurs one month after the end of the 2-year treatment phase. Information collected at study visits include blood and urine test results, safety assessments and treatment adherence. Information about the overall health status of each participant is collected every 5 years.

Studietype

Intervensjonell

Registrering (Antatt)

2000

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Australian Capital Territory
      • Garran, Australian Capital Territory, Australia, 2605
        • Rekruttering
        • The Canberra Hospital
        • Ta kontakt med:
          • Girish Talaulikar
    • New South Wales
      • Kingswood, New South Wales, Australia, 2747
        • Rekruttering
        • Nepean Blue Mountains Local Health District
        • Ta kontakt med:
          • Bhadran Bose
      • Kogarah, New South Wales, Australia, 2217
        • Rekruttering
        • St George Hospital
        • Ta kontakt med:
          • Sunil Badve
      • New Lambton Heights, New South Wales, Australia, 2305
        • Rekruttering
        • John Hunter Hospital
        • Ta kontakt med:
          • Bobby Chacko
      • Westmead, New South Wales, Australia, 2145
        • Rekruttering
        • Westmead Hospital
        • Ta kontakt med:
          • Vincent Lee
    • Queensland
      • Birtinya, Queensland, Australia, 4575
        • Rekruttering
        • Sunshine Coast Hospital and Health Service
        • Ta kontakt med:
          • Nicholas Gray
      • Douglas, Queensland, Australia, 4814
        • Rekruttering
        • Townsville University Hospital
        • Ta kontakt med:
          • Vikas Srivastava
      • Ipswich, Queensland, Australia, 4305
        • Rekruttering
        • West Moreton Hospital & Health Service
        • Ta kontakt med:
          • Sree Venuthurupalli
      • Southport, Queensland, Australia, 4215
        • Rekruttering
        • Gold Coast Hospital and Health Service
        • Ta kontakt med:
          • Jagadeesh Kurtkoti
    • South Australia
      • Adelaide, South Australia, Australia, 5000
        • Rekruttering
        • Royal Adelaide
        • Ta kontakt med:
          • Michael Collins
      • Elizabeth Vale, South Australia, Australia, 5112
        • Rekruttering
        • Lyell McEwin Hospital
        • Ta kontakt med:
          • Nitesh Rao
    • Victoria
      • Heidelberg, Victoria, Australia, 3084
        • Rekruttering
        • Austin Health
        • Ta kontakt med:
          • Sharon Ford
    • Western Australia
      • Murdoch, Western Australia, Australia, 6150
        • Rekruttering
        • South Metropolitan Health Service, Fiona Stanley Hospital
        • Ta kontakt med:
          • Suda Swaminathan
      • Dehradun, India, 248001
        • Har ikke rekruttert ennå
        • Max Superspeciality Hospital, Dehradun
        • Ta kontakt med:
          • Puneet Arora
      • Ghaziabad, India, 201012
        • Rekruttering
        • Max Superspecialty Hospital, Ghaziabad
        • Ta kontakt med:
          • Manoj Kumar Singhal
      • Puducherry, India, 607403
        • Rekruttering
        • Aarupadai Veedu Medical College & Hospital (AVMCH), Puducherry
        • Ta kontakt med:
          • Venkatesh A
    • Andhra Pradesh
      • Visakhapatnam, Andhra Pradesh, India, 530045
        • Rekruttering
        • Gitam Institute of Medical Sciences and Research
        • Ta kontakt med:
          • Murty Mandapaka
    • Bihar
      • Patna, Bihar, India, 800001
        • Rekruttering
        • Patna Medical College and Hospital
        • Ta kontakt med:
          • Harsh Vardhan
    • Chhattisgarh
      • Raipur, Chhattisgarh, India, 492002
        • Rekruttering
        • DKS Super Speciality Hospital, Raipur
        • Ta kontakt med:
          • Varun Agrawal
    • Dehradun
      • Dehradun, Dehradun, India, 248001
        • Rekruttering
        • Mysore Medical College
        • Ta kontakt med:
          • Puneet Arora
    • Gujarat
      • Ahmedabad, Gujarat, India, 380025
        • Rekruttering
        • GCS Medical College, Hospital & Research Centre
        • Ta kontakt med:
          • Suvika Patel
      • Vadodara, Gujarat, India, 390007
        • Rekruttering
        • Aman Hospital & Research Center Vadodara
        • Ta kontakt med:
          • Aman Khanna
    • Karnataka
      • Mangaluru, Karnataka, India, 575002
        • Rekruttering
        • Father Muller Medical College Hospital
        • Ta kontakt med:
          • Manjunath Kulkarni
    • Kerala
      • Meppādi, Kerala, India, 673511
        • Rekruttering
        • Dr Moopen's Medical College
        • Ta kontakt med:
          • Aneesh Basheer
    • Madhya Pradesh
      • Indore, Madhya Pradesh, India
        • Rekruttering
        • CARE-CHL Hospital
        • Ta kontakt med:
          • Isha Tiiwari
    • Tamil Nadu
      • Chennai, Tamil Nadu, India, 600024
        • Rekruttering
        • Medway Hospital
        • Ta kontakt med:
          • Shivakumar Dakshinamoorthy
    • Telangana
      • Hyderabad, Telangana, India, 500084
        • Rekruttering
        • Yashoda Hospital Hitec City
        • Ta kontakt med:
          • Mahesh Kota
      • Hyderabad, Telangana, India
        • Rekruttering
        • Apollo Hospitals
        • Ta kontakt med:
          • Haresh Patel
    • Uttar Pradesh
      • Lucknow, Uttar Pradesh, India, 226003
        • Rekruttering
        • Charak Hospital and Research Centre
        • Ta kontakt med:
          • Sakshi Jain
    • Uttarakhand
      • Dehradun, Uttarakhand, India, 248001
        • Rekruttering
        • Shri Guru Ram Rai Medical College and Shri Mahant Indiresh Hospital
        • Ta kontakt med:
          • Gaurav Shekhar Sharma
    • West Bengal
      • Kolkata, West Bengal, India, 700107
        • Rekruttering
        • Fortis Hospital
        • Ta kontakt med:
          • Upal Sengupta
      • Siliguri, West Bengal, India, 734012
        • Rekruttering
        • North Bengal Medical College & Hospital
        • Ta kontakt med:
          • Arpita Ray Chaudhury
      • Auckland, New Zealand, 1023
        • Rekruttering
        • Auckland City Hospital
        • Ta kontakt med:
          • Dr Helen Pilmore
      • Auckland, New Zealand, 2025
        • Rekruttering
        • Aotearoa Clinical Trials Trust, Middlemore Hospital
        • Ta kontakt med:
          • Kalpa Jayanatha
      • Auckland, New Zealand, 0620
        • Rekruttering
        • Health New Zealand, Te Whatu Ora Waitemata, North Shore Hospital
        • Ta kontakt med:
          • Ashik Hayat
      • Dunedin, New Zealand, 9016
        • Rekruttering
        • 201 Great King Street, Central Dunedin, Dunedin 9016, New Zealand
        • Ta kontakt med:
          • John Schollum
      • Palmerston North, New Zealand, 4442
        • Rekruttering
        • Midcentral - Palmerston North Hospital
        • Ta kontakt med:
          • Dr Curtis Walker
      • Whangarei, New Zealand, 0148
        • Rekruttering
        • Private Bag 9742 Maunu Road, Horahora, Whangārei 0148, New Zealand
        • Ta kontakt med:
          • Adam Mullan
    • Hawkes Bay
      • Hastings, Hawkes Bay, New Zealand, 4120
        • Rekruttering
        • Health New Zealand, Te Whatu Ora Te Matau a Maui, Hawke's Bay Hospital
        • Ta kontakt med:
          • Hussain Allawati
    • Barcelona
      • Badalona, Barcelona, Spania, 08916
        • Aktiv, ikke rekrutterende
        • Hospital Germans Trias i Pujol
      • Horta-Guinardó, Barcelona, Spania, 08035
        • Rekruttering
        • Vall d'Hebron University Hospital
        • Ta kontakt med:
          • Dr Maria Jose Soler Romeo
    • Espana
      • Valencia, Espana, Spania, 46010
        • Rekruttering
        • Hospital Clinico Universitario València (INCLIVA)
        • Ta kontakt med:
          • Prof Jose Luis Gorriz Teruel
      • Colombo, Sri Lanka, 00700
        • Rekruttering
        • National Hospital of Sri Lanka
        • Ta kontakt med:
          • Dr Mathu Selvarajah
      • Kandy, Sri Lanka, 20000
        • Rekruttering
        • Kandy National Hospital
        • Ta kontakt med:
          • Dr Nishantha Nanayakkara
      • Kurunegala, Sri Lanka
        • Rekruttering
        • Kurunegala Teaching Hospital
        • Ta kontakt med:
          • Dr Premil Rajakrishnan
      • Nugegoda, Sri Lanka, 10250
        • Rekruttering
        • Sri Jayewardenepura General Hospital
        • Ta kontakt med:
          • Dr Harshani Perera
      • Peradeniya, Sri Lanka, 20400
        • Rekruttering
        • Peradeniya Teaching Hospital
        • Ta kontakt med:
          • Dr Rajitha Abeysekera
      • Ragama, Sri Lanka, 11010
        • Rekruttering
        • Colombo North Teaching Hospital
        • Ta kontakt med:
          • Dr Nalaka Herath
    • Northern Province
      • Jaffna, Northern Province, Sri Lanka, 4000
        • Rekruttering
        • Jaffna Teaching Hospital
        • Ta kontakt med:
          • Dr. Brammah Thangarajah
    • Polonnaruwa
      • Colombo, Polonnaruwa, Sri Lanka, 51000
        • Rekruttering
        • National Nephrology Specialized Hospital
        • Ta kontakt med:
          • Dr Naseef Thaseem
    • Western Province
      • Dehiwala, Western Province, Sri Lanka, 10290
        • Rekruttering
        • University Hospital, Kotelawala Defence University
        • Ta kontakt med:
          • Dr Dilukshi Pilapitiya

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Age ≥ 18 years
  2. Known chronic kidney disease from any cause (eGFR ≥25 mL/min/1.73m2)
  3. Currently receiving standard of care treatment according to treating physician
  4. Eligible for randomisation in at least one recruiting domain-specific appendix
  5. Participant and treating physician are willing and able to perform trial procedures

Exclusion Criteria:

  1. Planned to commence kidney replacement therapy or kidney transplant surgery in next 6 months
  2. Life expectancy less than 6 months

To be included in any of the following DOMAINS the participant must met eligible for the PLATFORM (as listed above)

MRA domain

Inclusion Criteria:

  1. Urine albumin-creatinine ratio (uACR) >200 mg/g (22.6 mg/mmol) or urine protein-creatinine ratio (uPCR) >300 mg/g (33.9 mg/mmol) at time of screening.
  2. On a stable standard of care treatment for CKD, including a SGLT2i unless there is a documented reason not to be using a SGLT2i*, for 4 weeks before screening according to treating physician.
  3. Treating physician believes finerenone is clinically appropriate for the participant.
  4. Participant and treating physician are willing and able to perform MRA DSA procedures.
  5. Provision of written informed consent or eConsent following a fully informed discussion and prior to performing any MRA DSA related procedures

Exclusion Criteria:

  1. Recipient of kidney transplant
  2. Hyperkalaemia (serum potassium ≥5.0 mmol/L) at time of screening
  3. Current treatment with MRA, where the treating physician or patient is not willing to discontinue this medication. If willing to discontinue the MRA, the potential participant must be re-screened after they have been on stable standard of care treatment for 4 weeks without the MRA.
  4. Known allergy, intolerance or contraindication to MRAs
  5. Current treatment with strong CYP3A4 inhibitors
  6. Systolic BP <110 mmHg or diastolic BP<55 mmHg without antihypertensive therapy at time of screening
  7. Severe hepatic impairment (defined as Child-Pugh Class C)
  8. Adrenal insufficiency
  9. Currently pregnant or breast feeding, or intending to become pregnant

GLP-1 RA Domain

Inclusion Criteria

  1. Urine albumin-creatinine ratio (uACR) >200 mg/g (22.6 mg/mmol) or urine proteincreatinine ratio (uPCR) >300 mg/g (33.9 mg/mmol) at time of screening.
  2. On a stable standard of care treatment for CKD, including a SGLT2i and maximum tolerated ACEi/ARB unless there is a documented reason not to be using a SGLT2i, for 4 weeks before screening.
  3. HbA1c less than or equal to 10% (less than or equal to 86mmol/L)
  4. BMI ≥23 kg/m2 and < 50 kg/m2
  5. Treating physician believes semaglutide is clinically appropriate for the participant
  6. Participant and treating physician are willing and able to perform GLP-1 RA DSA procedures
  7. Provision of written informed consent or eConsent following a fully informed discussion and prior to performing any GLP-1 RA DSA related procedures

Exclusion Criteria

  1. Recipient of kidney transplant
  2. Major adverse cardiovascular events (MACE), consisting of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death, within 90 days prior to the day of screening
  3. Presently classified as being in New York Heart Association (NYHA) Class IV heart failure
  4. Personal or first-degree relative(s) with a history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid carcinoma (MTC)
  5. Previous episode of pancreatitis
  6. Uncontrolled thyroid disease TSH>6.0 mIU/L or <0.4mlU/L
  7. Type 1 diabetes
  8. Current treatment with a GLP-1 RA, where it is in the participant's best interests to continue the GLP-1 RA or where the treating physician or patient is not willing to discontinue this medication for a minimum of 4 weeks prior to randomisation and for the full duration of the trial (ie. 108 weeks if assigned to placebo).
  9. Known allergy, intolerance, or contraindication to GLP-1 RAs
  10. Currently pregnant or breast feeding, or intending to become pregnant or is of child-bearing potential, and not using a highly effective contraceptive method
  11. Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Faktoriell oppgave
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Finerenone

Finerenone 10mg or 20mg tablets

Finerenone 10mg or 20mg tablets, oral, once daily

Andre navn:
  • BAY94-8862
Placebo komparator: Placebo Finerenone

Finerenone matched placebo tablets

Finerenone matched placebo tablets, oral, once daily

Eksperimentell: Semaglutide

Semaglutide 1.0 mg or 2.4 mg pen injector

Semaglutide 1.0mg or 2.4mg pen injector, subcutaneous injection, once weekly

Placebo komparator: Placebo Semaglutide

Semaglutide matched placebo pen injector

Semaglutide matched pen injector, subcutaneous injection, once weekly

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Core Primary Outcome Measure
Tidsramme: From randomisation to week 108

The primary outcome is chronic eGFR slope. Chronic eGFR slope measures the rate of eGFR decline while on treatment. The duration of time over which chronic eGFR slope is computed can vary by domain and is determined by clinical considerations such as whether the investigational product can cause an acute decline in eGFR upon initiation. DSAs will specify the duration of time over which chronic eGFR slope is computed for the individual domain.

From randomisation to week 108
MRA Domain Primary Outcome Measure
Tidsramme: From week 4 to week 108

Chronic eGFR slope estimated from all available eGFR values from week 4 to the end of treatment. The final eGFR value that contributes to the primary outcome is the last eGFR measured while the participant is on treatment.

From week 4 to week 108
GLP1-RA Domain Primary Outcome Measure
Tidsramme: From week 0 to week 108

Chronic eGFR slope estimated from all available eGFR values from Week 0 to the end of treatment. The final eGFR value that contributes to the primary outcome is the last eGFR measured while the participant is on treatment.

From week 0 to week 108

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Core Protocol Secondary outcomes
Tidsramme: week 0 and 24 weeks

1. Change in albuminuria as measured by uACR (or uPCR if uACR unavailable) between week 0 and 24 weeks, measured as a continuous variable.

week 0 and 24 weeks
Core Protocol Secondary outcomes
Tidsramme: week 0 to end of washout

2. eGFR slope from week 0 to end of washout

week 0 to end of washout
Core Protocol Secondary outcomes
Tidsramme: week 0 to end of washout

3. Change in eGFR from week 0 to end of washout

week 0 to end of washout
Core Protocol Secondary outcomes
Tidsramme: between week 0 and 108 weeks

4. Composite outcome of proportion of participants experiencing a ≥40% eGFR decline between week 0 and 108 weeks, and proportion of participants developing kidney failure (defined as eGFR <15 mL/min/1.73m2 or chronic kidney replacement therapy start†) at 108 weeks.

between week 0 and 108 weeks
Core Protocol Secondary outcomes
Tidsramme: from start of study drug (week 0) to washout (week 108) or kidney failure

5. Time to a composite outcome of ≥40% eGFR decline from week 0 or kidney failure

from start of study drug (week 0) to washout (week 108) or kidney failure
Core Protocol Secondary outcomes
Tidsramme: at 108 weeks

6. All-cause mortality at 108 weeks

at 108 weeks
Core Protocol Secondary outcomes
Tidsramme: between week 0 and week 108

7. Proportion of participants experiencing one or more cardiovascular events (cardiovascular death, hospitalised heart failure, myocardial infarction, stroke)* between week 0 and week 108

between week 0 and week 108
Core Protocol Secondary outcomes
Tidsramme: from start of study drug (week 0) to end of washout (week 108)

8. Time to first occurrence of a cardiovascular event

from start of study drug (week 0) to end of washout (week 108)
Core Protocol Secondary outcomes
Tidsramme: from start of study drug (week 0) to end of treatment (up to week 104)

9. Safety and tolerability of treatment

from start of study drug (week 0) to end of treatment (up to week 104)
Core Protocol Secondary outcomes
Tidsramme: 6-monthly intervals from randomisation to week 108

10. Change in quality of life measured using the Quality of Life Impact Survey for Kidney Disease (QDISCKD) at 6-monthly intervals from randomisation to week 108.

6-monthly intervals from randomisation to week 108
MRA Domain Secondary Outcome
Tidsramme: from start of study drug (week 0) to end of washout (week 108)

MRA DSA has a domain-specific secondary outcome that evaluates the time to the composite of ≥57% eGFR decline from week 0 or kidney failure

from start of study drug (week 0) to end of washout (week 108)
GLP-1 RA Domain Secondary Outcome
Tidsramme: from start of study drug (week 0) to end of washout (week 108)

1. Change in eGFR slope from Week 0 to Week 108.

from start of study drug (week 0) to end of washout (week 108)
GLP-1 RA Domain Secondary Outcome
Tidsramme: from start of study drug (week 0) to end of washout (week 108)

2. Time to composite of onset of kidney failure (initiation of long-term dialysis, kidney transplantation, or a reduction in the eGFR to <15 mL per minute per 1.73 m2 sustained for ≥28 days), a sustained (for ≥28 days) 50% or greater reduction in eGFR from Week 0, or death from kidney-related or cardiovascular causes.

from start of study drug (week 0) to end of washout (week 108)
GLP-1 RA Domain Secondary Outcome
Tidsramme: from Week 0 to Week 108

3. Time to first occurrence of onset of persistent ≥50% reduction in eGFR from Week 0 to Week 108

from Week 0 to Week 108
GLP-1 RA Domain Secondary Outcome
Tidsramme: from start of study drug (week 0) to end of washout (week 108)

4. Time to first occurrence of a composite outcome of major adverse cardiovascular events (MACE) consisting of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death

from start of study drug (week 0) to end of washout (week 108)
GLP-1 RA Domain Secondary Outcome
Tidsramme: from start of study drug (week 0) to end of washout (week 108)

5. Time to occurrence of all-cause death

from start of study drug (week 0) to end of washout (week 108)
GLP-1 RA Domain Secondary Outcome
Tidsramme: from Week 0 to Week 108

6. Change in body weight from Week 0 to Week 108

from Week 0 to Week 108
GLP-1 RA Domain Secondary Outcome
Tidsramme: Week 0 to Week 108

7. Change in HbA1c from Week 0 to Week 108

Week 0 to Week 108
GLP-1 RA Domain Secondary Outcome
Tidsramme: from Week 0 to Week 108

8. Change in systolic blood/diastolic blood pressure from Week 0 to Week 108

from Week 0 to Week 108
GLP-1 RA Domain Secondary Outcome
Tidsramme: from Week 0 to Week 108

9. Change in NT-proBNP from Week 0 to Week 108

from Week 0 to Week 108
GLP-1 RA Domain Secondary Outcome
Tidsramme: from randomisation to Week 108

10. Change in health status measured using the 23-item Kansas City Cardiomyopathy Questionnaire (KCCQ) at 6-monthly intervals from randomisation to Week 108

from randomisation to Week 108
GLP-1 RA Domain Secondary Outcome
Tidsramme: Week 0 to end of trial

11. Incidence of AEs and the following medical events of special interest (MESI) from Week 0 to end of trial:

  1. Neoplasm (malignant and benign)
  2. Pancreatitis, or persistent abdominal pain leading to a suspicion of pancreatitis
  3. Acute gallstone disease (biliary colic or acute cholecystitis)
  4. Thyroid disease
  5. Cardiac arrhythmia (specifically, atrial fibrillation, atrial flutter, ventricular tachycardia, ventricular fibrillation, torsade de pointes, second degree heart block type 2, third degree heart block, and symptomatic bradycardia requiring pacemaker placement)
  6. Severe hypoglycaemic episodes
  7. Immunogenicity events (allergic reactions, immune-complex disease, and lack of efficacy)
  8. Adverse events leading to treatment discontinuation (if not any of the mentioned MESIs)
  9. Ocular adverse events
  10. Suspicion of transmission of infectious agents
Week 0 to end of trial

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studiestol: Sradha Kotwal, The George Institute
  • Studiestol: Hiddo Lambers Heerspink, The George Institute

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

4. september 2024

Primær fullføring (Antatt)

31. desember 2029

Studiet fullført (Antatt)

31. desember 2029

Datoer for studieregistrering

Først innsendt

21. september 2023

Først innsendt som oppfylte QC-kriteriene

21. september 2023

Først lagt ut (Faktiske)

28. september 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

29. september 2026

Sist bekreftet

1. august 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Trial data will be made available as a resource for future unspecified research, subject to any prior contractual obligations. Researchers wishing to gain access to the study resources will be required to submit an application for review by the Platform Oversight Committee, including a detailed project description, a list of data requested, and evidence of ethical approval. De-identified data extracts will be made available to approved proposals, and will not include data obtained from data linkage with local registries.

IPD-delingstidsramme

TBC

Tilgangskriterier for IPD-deling

Assessments of data requests will be based on sound science, benefit-risk balancing and research team expertise.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • ICF
  • CSR

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere